LeMaitre Vascular Inc. (NASDAQ:LMAT) shares traded down 2.9% on Thursday . The stock traded as low as $13.79 and last traded at $13.83, with a volume of 74,273 shares trading hands. The stock had previously closed at $14.25.

Several research analysts recently weighed in on the company. Brean Capital reaffirmed a “buy” rating on shares of LeMaitre Vascular in a research note on Tuesday, May 3rd. Zacks Investment Research upgraded LeMaitre Vascular from a “hold” rating to a “buy” rating and set a $18.00 price target for the company in a research report on Thursday, May 5th. Roth Capital increased their price target on LeMaitre Vascular from $18.00 to $18.50 and gave the company a “buy” rating in a research report on Tuesday, May 3rd. Finally, Canaccord Genuity reiterated a “buy” rating and issued a $18.00 price target (up previously from $6.00) on shares of LeMaitre Vascular in a research report on Tuesday, May 3rd. One investment analyst has rated the stock with a hold rating and eight have assigned a buy rating to the stock. LeMaitre Vascular has an average rating of “Buy” and a consensus price target of $17.61.

The firm has a market capitalization of $254.18 million and a PE ratio of 30.80. The company has a 50 day moving average price of $14.36 and a 200 day moving average price of $14.83.

LeMaitre Vascular (NASDAQ:LMAT) last released its earnings results on Monday, May 2nd. The company reported $0.11 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.10 by $0.01. Equities research analysts predict that LeMaitre Vascular Inc. will post $0.48 earnings per share for the current fiscal year.

In other LeMaitre Vascular news, Director David B. Roberts sold 1,766 shares of the company’s stock in a transaction that occurred on Monday, April 18th. The stock was sold at an average price of $16.10, for a total value of $28,432.60. Following the sale, the director now owns 147,136 shares in the company, valued at $2,368,889.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, CEO George W. Lemaitre sold 110,189 shares of the company’s stock in a transaction that occurred on Monday, May 9th. The shares were sold at an average price of $16.17, for a total value of $1,781,756.13. Following the completion of the sale, the chief executive officer now owns 3,549,133 shares in the company, valued at approximately $57,389,480.61. The disclosure for this sale can be found here.

Other hedge funds have added to or reduced their stakes in the company. GSA Capital Partners LLP raised its stake in LeMaitre Vascular by 12.6% in the fourth quarter. GSA Capital Partners LLP now owns 185,903 shares of the company’s stock valued at $3,207,000 after buying an additional 20,785 shares in the last quarter. Russell Frank Co raised its stake in LeMaitre Vascular by 24.8% in the fourth quarter. Russell Frank Co now owns 113,832 shares of the company’s stock valued at $1,992,000 after buying an additional 22,656 shares in the last quarter. Cornerstone Capital Management Holdings LLC. raised its stake in LeMaitre Vascular by 337.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 64,289 shares of the company’s stock valued at $1,109,000 after buying an additional 49,589 shares in the last quarter. American Century Companies Inc. acquired a new stake in LeMaitre Vascular during the fourth quarter valued at about $1,209,000. Finally, Dimensional Fund Advisors LP raised its stake in LeMaitre Vascular by 8.8% in the fourth quarter. Dimensional Fund Advisors LP now owns 866,308 shares of the company’s stock valued at $14,944,000 after buying an additional 70,118 shares in the last quarter.

LeMaitre Vascular, Inc is a provider of medical devices for the treatment of peripheral vascular disease. The Company and its subsidiaries develop, manufacture and market medical devices and implants used primarily in the field of vascular surgery. It operates in the design, marketing, sales and technical support of medical devices and implants for the treatment of peripheral vascular disease industry segment.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.